Jun 7, 2010 by Brian Orelli, PhDPfizer's Drug Treats Some Patients Very Well IndeedIt's no Lipitor, but investors will take it.
Jun 7, 2010 by Brian Orelli, PhDBristol Investors Go Crazy Wild. Are They Justified?Promising ASCO data with caveats.
Jun 4, 2010 by Brian Orelli, PhDOut With Drugs, in With Medical DevicesJohnson & Johnson asks investors to look the other way.
Jun 2, 2010 by Brian Orelli, PhDLittle Surprise. Big Stock Move.Investors like Amgen's early approval.
Jun 2, 2010 by Brian Orelli, PhDTake Your Low Margins and Shove 'EmNovo Nordisk ain't selling to Greece no more.
Jun 1, 2010 by Brian Orelli, PhDSave Your Money, DendreonForget the fancy presentations -- just build more factories.
May 28, 2010 by Brian Orelli, PhDPfinally! Pfizer Gets a Clinical-Trial Win!But it's only a superficial win.
May 28, 2010 by Brian Orelli, PhDThis Drug Doesn't Work. But All Is Not Lost.Novartis cancer drug fails one trial, but there's still hope.
May 28, 2010 by Brian Orelli, PhDIs It Time to Make Money Investing in Genetic Testing?Easier said than done.
May 28, 2010 by Brian Orelli, PhDInnovators Will Rule the Economic CrisisRoche's CEO says two areas of health care can prosper. I agree.
May 27, 2010 by Brian Orelli, PhDEver-Evolving Stent Technology (and How to Profit From It)Stay ahead of the curve.
May 27, 2010 by Brian Orelli, PhDThis Rabid Agency Could Permanently Damage Your PortfolioThe FDA has gotten a little out of control.
May 27, 2010 by Brian Orelli, PhDNow That's What I Call a Healthy Dividend IncreaseUnitedHealth ups its token dividend substantially.
May 26, 2010 by Brian Orelli, PhDGreat Data, but Were You Expecting Otherwise?Vertex sets the bar high, but well south of the moon.
May 26, 2010 by Brian Orelli, PhDIs This 4,000-Liter Bioreactor Half-Full?Or half-empty? Only time will tell for Genzyme.
May 26, 2010 by Brian Orelli, PhDBlockbuster Drugs Aimed at Busting MSMultiple sclerosis is a large market with more entrants coming.
